Amgen Builds Up Future Launches As Oncology Biosimilars Slide

Firm Looks To Amjevita, Along With Stelara And Eylea Rivals, For Future Growth

 
• By Dave Wallace

Amgen’s biosimilars sales are on the decline, largely due to erosion of its oncology portfolio. However, the debut of first US Humira rival Amjevita, along with planned versions of Stelara and Eylea, are expected to push the segment back into growth.

Wooden businessman down up stairs
As Amgen’s oncology biosimilars decline, a lift will come from new products • Source: Shutterstock

On the day that Amgen launched its Amjevita (adalimumab-atto) debut US rival to Humira, industry onlookers might have expected the company to sound upbeat about its biosimilars business.

However, during the firm’s same-day fourth-quarter earnings call investors and analysts were given a candid snapshot of the decline seen in its existing portfolio of oncology biosimilars, albeit tempered by optimism for the future of the biosimilars segment thanks to the Amjevita

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products